Sibylle Loibl
Leads the German Breast Group, whose GeparX trials defined neoadjuvant chemotherapy and immunotherapy in breast cancer.
Sibylle Loibl chairs the GBG and led GeparSixto, GeparNuevo, and GeparDouze, trials of carboplatin and immunotherapy before surgery in triple-negative breast cancer that shaped today's standards.
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Everyone with HER2-negative early breast cancer that meets high-risk criteria should be offered germline BRCA testing, because a positive result now changes treatment: a year of olaparib after chemotherapy reduces relapse and death. It does not apply to low-risk tumours, HER2-positive disease, or somatic-only BRCA mutations.
HER2-positive breast cancer is now routinely treated before surgery so that the pathology result can guide what comes after: patients with no residual cancer continue trastuzumab (with or without pertuzumab), while those with residual disease switch to T-DM1. This model of using the tumour's response as a test has since been copied in triple-negative and other cancers.
Pages like this
not linked directly; found by shared links- PersonGunter von Minckwitz
Shares German Breast Group (GBG), KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, HER2-positive breast cancer.
- TrialDESTINY-Breast11
Shares KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, Pathologic complete response (pCR), HER2-positive breast cancer.
- PersonZhi-Ming Shao
Shares KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, Triple-negative breast cancer (TNBC).
- PersonMartine Piccart
Shares ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, HER2-positive breast cancer.
- IdeaADC for residual disease after KEYNOTE-522
Shares KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Pathologic complete response (pCR), Triple-negative breast cancer (TNBC).
- PersonCharles E. Geyer Jr.
Shares KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- TermResidual cancer burden (RCB)
Shares KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, Triple-negative breast cancer (TNBC).
- PersonLaura J. Esserman
Shares Pathologic complete response (pCR), HER2-positive breast cancer, Triple-negative breast cancer (TNBC).